673 Delay in diagnosis and treatment of breast cancer in northern Norway. What is the impact?

1995 ◽  
Vol 31 ◽  
pp. S141
Author(s):  
J. Norum ◽  
E.A. Wist
Keyword(s):  
Breast Cancer ◽  
Diagnosis And Treatment ◽  
Northern Norway ◽  
Delay In Diagnosis ◽  
The Impact

scholarly journals Evaluation of time to perform surgery in patients with breast cancer assisted at hospital federal da lagoa (hfl), in rio de janeiro, from january 2014 to january 2017

Mastology ◽  
2020 ◽  
Vol 30 (Suppl 1) ◽  
Author(s):  
Erica Motroni de Almeida ◽  
Rafael Henrique Szymanski Machado
Keyword(s):  
Breast Cancer ◽  
Retrospective Study ◽  
Adjuvant Chemotherapy ◽  
Survival Rates ◽  
Malignant Lesion ◽  
Definitive Treatment ◽  
Delay In Diagnosis ◽  
Lower Survival ◽  
Mean Waiting Time ◽  
The Impact

Objectives: The objective of this study was to assess the period of time elapsed between the date of biopsy and the date of surgery of patients with breast cancer (BC) assisted at the Mastology Service of HFL, from January 2014 to January 2017. We excluded from this analysis those patients with distant metastasis and the ones submitted to neoadjuvant chemotherapy. Introduction: Initial studies about the consequences on prognosis of the delay in diagnosis and treatment of BC tend to show that the longer the delay, the higher the disease staging at diagnosis; which, consequently, leads to lower survival rates. Methods: Retrospective study based on the analysis of medical records. We calculated the time elapsed between the date of biopsy of the malignant lesion and the date of the oncological surgery. The patients were divided in 3 groups regarding the time elapsed between biopsy and surgery: <60 days, 60 to 90 days and >90 days. Results: The mean waiting time for surgery was of 225.49 days. Only 2 patients (1.80%) waited less than 60 days. Seven patients (6.31%) were operated between 61 and 90 days, and the great majority of patients (102, in absolute numbers), waited for more than 90 days (90.89%). Discussion: Most studies associate the delay in diagnosis and BC treatment with lower survival rates. In a multivariate analysis, major delays to start the treatment were a significant risk factor for the reduction in survival. The delay in the surgical treatment of younger women (number of weeks between the date of diagnosis and date of definitive treatment) was assessed in a retrospective, case-control study published in 2013, which used data from the California Cancer Registry Database. In this study, the five-year survival of women treated with surgery who waited more than 6 weeks was 80%, in comparison to 90% among those whose delay was shorter than 2 weeks. Another retrospective study assessed the impact of the delay of the beginning of treatment after the biopsy confirmed BC. This analysis showed that the delay to begin the first treatment longer than or equal to 60 days was associated with worse specific survival rates. Gagliato et al showed the impact of the delay to start adjuvant chemotherapy in patients with BC in several stages, and with different tumor subtypes. The results showed worsened survival rates when the beginning of adjuvant chemotherapy was delayed in all of the study groups. Conclusion: Considering the data in this study and data from several others regarding the negative impact of delay in BC treatment, it is clear that efforts in all spheres of the government should be made so that the healing and survival rates can improve.

Assessment of the treatment results in patients with breast cancer coexisting with pregnancy: A single-center observational study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e12566-e12566
Author(s):  
Anna Skrzypczyk-Ostaszewicz ◽  
Agnieszka I. Jagiello-Gruszfeld ◽  
Jerzy Giermek ◽  
Zbigniew Nowecki
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Cancer Diagnosis ◽  
Disease Free Survival ◽  
Breast Cancer Diagnosis ◽  
Diagnosis And Treatment ◽  
Free Survival ◽  
The Impact ◽  
Disease Free

e12566 Background: This study discusses the analysis of the prospectively collected material on pregnant patients treated for breast cancer at the Department of Breast Cancer and Reconstructive Surgery of the Maria Skłodowska-Curie National Oncology Institute - National Research Institute (until 2020: Oncology Center - Institute) in Warsaw, in the years 1995 - 2020. 84 patients were included into the final analysis and 72 children were assessed simultaneously. Methods: The paper summarizes information on the diagnosis and treatment of breast cancer during pregnancy, the course of pregnancy and childbirth and the birth parameters of children i.e. weight, length and Apgar score, as well as the dependencies between them, mainly the impact of some breast cancer, diagnosis and treatment process features on the newborns. The patietnt’s survavial - DFS ( disease free survival) and OS ( overall survival) - was also analyzed. The course of breast cancer diagnosis and treatment data were obtained from the patients’ medical documentation (medical records) and from information provided by the mothers during follow-up visits and read in the children's health books. In order to answer the research questions, statistical analyzes were conducted using the IBM SPSS Statistics 26 package. Results: In the analyzed period, the disease recurrence was recognized in 34 (40.5%) patients, and 24 (28.6%) patients died. The median disease-free survival (DFS) was 12.3 years (147.5 months), and the median overall survival (OS) was not reached during the follow-up period. The estimated 5-year survival rates for DFS and OS were 57.9% and 74.5% respectively, and for 10-year survival - 51.4% and 64.5%. The study showed a statistically significant relationship between the baseline clinical advancement and DFS. It has been also analyzed how the diagnosis, treatment and method of pregnancy termination changed in two time periods (1995-2012 and 2013-2020). There were no statistically significant differences in survival - both DFS and OS - between the group of patients treated before and after 2012. In the assessment of the impact of some factors on the birth children parameters (weight and length), statistically significant results were obtained for: pregnancy advancement at diagnosis, breast cancer stage at diagnosis, pregnancy advancement at the start of chemotherapy, the chemotherapy regimen (classic or dose-dense), the number of cycles of chemotherapy given during pregnancy, and the number of drugs used in supportive treatment. Conclusions: The entire analysis has become not only an insightful characteristic of the studied group, but also these results may be important in everyday clinical practice and may help to optimize the management of an extremely complex and difficult situation, which is the coexistence of pregnancy with a malignant disease that threatens the mother’s life.

Socioeconomic Factors, Health Behavior, and Late-Stage Diagnosis of Breast Cancer: Considering the Impact of Delay in Diagnosis

2018 ◽  
Vol 18 (3) ◽  
pp. 239-245 ◽  
Author(s):  
Mostafa Dianatinasab ◽  
Mohammad Mohammadianpanah ◽  
Nima Daneshi ◽  
Mohammad Zare-bandamiri ◽  
Abbas Rezaeianzadeh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Health Behavior ◽  
Socioeconomic Factors ◽  
Late Stage ◽  
Delay In Diagnosis ◽  
Late Stage Diagnosis ◽  
The Impact

scholarly journals The Impact of a Breast Cancer Diagnosis on Women´s Work Status

2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 120s-120s
Author(s):  
M. Fisher ◽  
L. Barry ◽  
M. Pitcher ◽  
L. Storer
Keyword(s):  
Breast Cancer ◽  
Cancer Diagnosis ◽  
Health Care Professionals ◽  
Employment Status ◽  
Financial Stress ◽  
Diagnosis And Treatment ◽  
Treatment Modalities ◽  
Work Status ◽  
Paid Employment ◽  
The Impact

Background: Many women diagnosed with breast cancer are of working age at the time of diagnosis, so the impact of a diagnosis and treatment regimen on their lives can cause financial stress-partly by impacting on their ability to continue in paid employment. The financial fallout from not working, changes in employment status and the hidden costs associated with cancer treatment can add to financial toxicity. Aim: Our aim was to identify changes in work status after a diagnosis of breast cancer. Our secondary aim was to determine if there was a correlation between different treatment modalities and work status at 12 month follow-up. Finally, we wanted to consider the role of treatment and change in work status on the financial stress experienced by patients after their diagnosis and treatment. Methods: An audit of the medical record of women who present to Western Health with a diagnosis of early breast cancer and consequently attended the nurse led breast cancer survivorship clinic (SC) between October 2015 and October 2016 was performed to identify employment status at diagnosis and at review in SC 12 months later. Results: 114 patients attended the SC in a 1 year period- 2 were males and both retired at diagnosis. The records of 111 women were reviewed. 46 of the 84 women < 65 years, were in paid employment at diagnosis. 38 of these 46 women were working in some capacity at 12 month review though only 28 were working the same, having decreased hours since diagnosis. 17 of the 111 (15%) women reported financial stress at the 12 month review. 9 of the 19 (42%) women with changed work status reported financial stress. 2 of the 28 (7%) women working the same hours reported financial stress. 14 of the 19 (74%) women who had changed work status had chemotherapy. 65% of those who reported financial stress (11/17) had chemotherapy as part of their treatment. 10/19 (53%) had changed or stop working since axillary dissection. Conclusion: Our data suggest that 83% of women returned to work in some capacity- most at the same level, and these women were unlikely to report financial stress. Women who returned to work at reduced hours, increased hours, or did not return to work at all were more likely to report significant financial concerns at one year postdiagnosis. Health care professionals as part of ongoing care should be aware of the financial impact a cancer diagnosis and its treatments, and should aim to refer appropriately.

scholarly journals Information Needs of Women with Breast Cancer: A Review of the Literature

2020 ◽  
Vol 9 (1) ◽  
pp. 30
Author(s):  
Abbas Sheikhtaheri ◽  
Azin Nahvijou ◽  
Esmat Mashoof
Keyword(s):  
Breast Cancer ◽  
Sexual Health ◽  
Information Needs ◽  
Daily Activities ◽  
Diagnosis And Treatment ◽  
Sufficient Information ◽  
High Survival ◽  
Review Of The Literature ◽  
Self Image ◽  
The Impact

Introduction: Breast cancer is one of the most common cancers and a serious concern for women's health. Providing sufficient information to these patients increases the level of their participation and improves the quality of their care. Therefore, given the high survival rate of this cancer, it is necessary to understand their information needs. The purpose of this study was to evaluate the information needs of women with breast cancer.Material and Methods: The study is a systematic review of the literature. A search of the databases of PubMed, Scopus, Science Direct and ProQuest has been conducted on studies published in English over the period 2010-2017. 2881 articles were retrieved and evaluated for title, abstract and full text and after eliminating duplicate and unrelated cases, 18 articles related to the purpose of the study were selected. The articles were then analyzed using content analysis.Results: Of the 2881 retrieved articles, 18 studies on the information needs of patients with breast cancer were finally reviewed. According to these studies, most information needs were in the areas of diagnosis and treatment (first rank), daily activities (second rank), disease acceptance and self-image (third rank), personal and family life (fourth rank) and sexual health (fifth rank). The most important information needs in the field of diagnosis and treatment was outcomes and side effects of treatment, in the area of daily activities on the impact of disease on social activity, in the area of disease acceptance and self-image was breast reconstruction, body appearance and need for consultation, in the area of personal life, cancer risk for the family and in the area of sexual health was the effect of cancer on sexual attraction were the most cited needs.Conclusion:Providing information to patients is one of the most important factors in supporting cancer care and understanding the information needs is the first step in seeking information. Patients with breast cancer are interested in receiving information that will help them understand cancer, make decisions about it, and manage their treatment.

scholarly journals Impact of COVID-19 on Outcomes for Patients With Cervical Cancer in India

2021 ◽  
pp. 716-725
Author(s):  
Nidhi Gupta ◽  
Akashdeep Singh Chauhan ◽  
Shankar Prinja ◽  
Awadhesh Kumar Pandey
Keyword(s):  
Cervical Cancer ◽  
Primary Care Physicians ◽  
Early Stage ◽  
Treatment Interruption ◽  
Diagnosis And Treatment ◽  
Delay In Diagnosis ◽  
Delayed Treatment ◽  
Life Years ◽  
Early Stage Cervical Cancer ◽  
The Impact

PURPOSE The COVID-19 pandemic has placed unprecedented demands on the health system. This led to delays in the initiation and completion of cancer treatment. We assessed the long-term health consequences because of the delay in diagnosis and treatment for cervical cancer due to COVID-19 in India. METHODS We used a Markov-model–based analysis assessing the lifetime health outcomes of the cohort of women population at risk from cervical cancer in India. The decrease in survival for those with the treatment interruption was calculated based on the number of days the treatment was extended beyond the standard duration. Furthermore, to model the impact of late diagnosis and delayed treatment initiation, the patients were assumed to have upstaged during the delay period, as per natural progression of disease. RESULTS We estimate 2.52% (n = 795) to 3.80% (n = 2,160) lifetime increase in the deaths caused by cervical cancer with treatment restrictions ranging from 9 weeks to 6 months, respectively, as compared to no delay. On the contrary, 88-238 deaths because of COVID-19 disease are estimated to be saved during this restriction period among the patients with cervical cancer. Overall, the excess mortality because of cervical cancer led to 18,159-53,626 life-years being lost and an increase of 16,808-50,035 disability-adjusted life-years. CONCLUSION Delays in diagnosis and treatment are likely to lead to more cervical cancer deaths as compared to COVID-19 mortality averted among the patients with cervical cancer. Health systems must reorganize in terms of priority setting for provision of care, starting with prioritizing the treatment of patients with early-stage cervical cancer, increasing use of teleconsultation, and strengthening the role of primary care physicians in provision of cancer care.

scholarly journals Czas oczekiwania na postawienie diagnozy i rozpoczęcie leczenia w przypadku złośliwego nowotworu piersi oraz wpływ pomiaru na poprawę standardu realizowanych świadczeń

2021 ◽  
Vol 18 (3) ◽  
pp. 227-235
Author(s):  
Anna Andrzejczak ◽  
Ewelina Żarłok ◽  
Karolina Osowiecka ◽  
Luiza Kańczuga-Koda ◽  
Sergiusz Nawrocki
Keyword(s):  
Breast Cancer ◽  
Waiting Time ◽  
Core Needle Biopsy ◽  
Cancer Care ◽  
Needle Biopsy ◽  
Waiting Times ◽  
Diagnosis And Treatment ◽  
Core Needle ◽  
Malignant Breast ◽  
The Impact

Waiting Times for Diagnosis and Treatment in Breast Cancer and the Impact of Measurement on the Improvement of the Standard of Services Provided Mortality rates for malignant breast cancer are rising in Poland. This is a subject of growing concern and a focus of public debate about cancer care in Poland. The following paper presents a case study—an attempt to measure and analyze waiting times for diagnosis and treatment in breast cancer. The survey was carried out in one of the regional cancer care centers in Poland. The data were collected solely from hospital information systems. The overall waiting time (mammography to treatment) was median 35,5 days. Waiting time since diagnosis (results of core needle biopsy to treatment) was median 27,5 days. The analysis has been conducted twice. In between the center implemented several organizational changes. They resulted in shortening of waiting time for mammogram description—from 4 to 1 day (median) also the waiting times for core needle biopsy result has been shortened—from 6 to 4 days (median). However, the overall waiting time has not changed significantly.

scholarly journals Impact of the COVID-19 pandemic on breast cancer diagnosis

Mastology ◽  
2020 ◽  
Vol 30 ◽  
Author(s):  
Cícera Chaves Lôbo ◽  
Luiz Gonzaga Porto Pinheiro ◽  
Paulo Henrique Diógenes Vasques
Keyword(s):  
Breast Cancer ◽  
Cancer Diagnosis ◽  
Delayed Diagnosis ◽  
Breast Cancer Diagnosis ◽  
Diagnosis And Treatment ◽  
Control Objective ◽  
Screening Coverage ◽  
Reference Service ◽  
The Impact ◽  
Series Study

Introduction: In 2020, a total of 2,510 new cases of breast cancer were estimated in Ceará State, 14% above the figures of 2019. In the context of the COVID-19 pandemic, postponing screening and assessing the risks and benefits of elective procedures was needed, rescheduled until after their control. Objective: We sought to identify the impact of the COVID-19 pandemic in the care of a Reference Service for Breast Cancer Diagnosis. Methods: Time series study, with analysis of the production of the consultations carried out from March to June of the current year in a service located in Fortaleza City, Ceará State. Results: There was a reduction of up to 84% in the services offered, with emphasis on mammography and ultrasound procedures, with 95 and 100%, respectively. The diagnosis of new cases and the performance of surgeries reduced by up to 60 and 56%, respectively. The months with the greatest impact were April and May, with a progressive resumption in June. Conclusion: The study evaluated a reference service of relevance in the state reality. Considering that many cases are identified during screening, postponing mammograms contributed to a delayed diagnosis. The findings are believed to pose severe consequences, considering the annual increase in the incidence of the disease, the low screening coverage, the high number of cases in advanced staging, the ascending mortality, and the low supply of diagnostic services. Diverting attention exclusively to the pandemic represents a worldwide challenge, but cancer is an important cause of morbidity and mortality, and cannot be neglected. There is concern that delaying screening, diagnosis, and treatment of breast cancer may cost more lives than COVID-19 itself. Post-pandemic requires planning to promote harm reduction resulting from the delay in the diagnosis and treatment of the repressed demand, in a disaggregated and overloaded system.

Sign in / Sign up

Export Citation Format

Share Document